POSITIONAL THERAPY DEVICE FOR SLEEP APNEA BUSINESS PLAN

I. Executive Summary

Company Description

SomniGuide—named to combine somni (sleep) and guide—operates in the medical technology sector from Austin, Texas, delivering smart wearable solutions for sleep health. We sell a product line of non-invasive positional therapy devices: the entry-level Lite and the advanced Pro, both paired with a proprietary mobile app. Our devices use advanced haptic feedback to reduce snoring and positional obstructive sleep apnea without masks or machines. One-line: we turn wearable haptics and data into clinically minded, home-ready sleep therapy.

We design, manufacture, and distribute devices, maintain the app and cloud analytics, and run clinical validation and patient support. Our differentiation is clinical focus, integrated data-driven therapy, and a spectrum of SKUs from affordable to advanced. Target customers are adults diagnosed with positional obstructive sleep apnea and chronic snorers plus their sleep partners, reached through sleep clinics, DTC channels, and B2B clinic partnerships. Short-term goals: launch in 2026, complete 12-month clinical validation, and reach 15,000 users by end of 2027. Long-term goals: secure 3 clinical partnerships, expand to Medicare-eligible channels, and reach 250,000 active users within five years. One-line: clinical rigor plus scalable channels drive durable adoption and revenue.

Problem

Millions of Americans suffer from snoring and positional obstructive sleep apnea when they sleep on their back, causing daytime fatigue, impaired cognition, and higher long-term cardiovascular and metabolic risk. Partners also experience sleep disruption, increasing household stress and care burden.

CPAP is effective but bulky, intrusive, and has low long-term compliance. There is no widely adopted, comfortable method that prevents supine sleeping through subtle intervention without fully waking the user. The market lacks a small, wearable, discreet positional therapy device users will actually wear nightly. One-liner: Solve back-sleeping comfortably, restore sleep for users and partners, and capture demand.

Solution

Millions of Americans suffer poor sleep and health risks from positional snoring and mild-to-moderate sleep apnea. Traditional CPAP adherence is low and basic positional aids lack effectiveness and data, leaving patients and partners with chronic sleep disruption and cardiovascular risk.

We offer a line of smart wearables—Classic, Pro, and Lite—that detect back-lying events and deliver calibrated vibrations to prompt position shifts while pairing with a mobile app for sleep-trend reports and clinician sharing. Real-world use shows gentle vibrations reduce back-sleep minutes without waking partners. Production targets for 2030: 60,000 Classic, 30,000 Pro, and 55,000 Lite units annually. One-liner: discreet, data-enabled positional therapy that improves compliance and measurable sleep outcomes.

Mission Statement

We improve sleep health with non-invasive wearable technology that treats positional sleep disorders.

We provide comfortable, data-driven devices grounded in clinical integrity and user-centered design to make restorative sleep accessible, reduce the health risks of snoring and apnea, and improve quality of life for users and their families.

Key Success Factors

Our success rests on proprietary tech, strong IP, fast financial returns, seasoned leadership, multi-channel sales, and clinical validation.

• Proprietary haptic feedback technology that differentiates product performance.
• $60,000 in initial patent filings underpinning a growing intellectual property portfolio.
• Rapid financial efficiency: 2-month break-even and 13-month payback period.
• Experienced leadership: CEO/Medical Director and Lead Hardware Engineer driving clinical and technical excellence.
• Go-to-market breadth and credibility: multi-channel sales, tiered pricing, and ongoing clinical trials for physician support.

Financial Summary

Brief financial snapshot for the Executive Summary showing revenue, profitability, and investor returns.

Financial requirements: maintain a minimum cash reserve of $1,102,000; breakeven achieved Feb-26 (2 months); payback period 13 months; target IRR 18.73% and ROE 34.34% for investors.

Overall outlook: strong, scalable revenue growth with improving EBITDA and attractive investor returns.

Funding Requirements

We require $2,704,350 to cover product development, 13-month operating runway, go-to-market, initial team, and a minimum $1,102,000 cash reserve to reach Year 1 revenue targets and a 13-month payback.